These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33649336)

  • 1. Immunomodulating nano-adaptors potentiate antibody-based cancer immunotherapy.
    Jiang CT; Chen KG; Liu A; Huang H; Fan YN; Zhao DK; Ye QN; Zhang HB; Xu CF; Shen S; Xiong MH; Du JZ; Yang XZ; Wang J
    Nat Commun; 2021 Mar; 12(1):1359. PubMed ID: 33649336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orchestrating NK and T cells via tri-specific nano-antibodies for synergistic antitumor immunity.
    Ye QN; Zhu L; Liang J; Zhao DK; Tian TY; Fan YN; Ye SY; Liu H; Huang XY; Cao ZT; Shen S; Wang J
    Nat Commun; 2024 Jul; 15(1):6211. PubMed ID: 39043643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing Natural Killer and CD8
    Ravindranath MH; Filippone EJ; Devarajan A; Asgharzadeh S
    Monoclon Antib Immunodiagn Immunother; 2019 Apr; 38(2):38-59. PubMed ID: 31009335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression.
    Nakajima F; Khanna A; Xu G; Lagman M; Haschemeyer R; Mouradian J; Wang JC; Stenzel KH; Rubin AL; Suthanthiran M
    Proc Natl Acad Sci U S A; 1994 Aug; 91(17):7889-93. PubMed ID: 8058730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
    Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B
    Front Immunol; 2018; 9():2873. PubMed ID: 30574146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing tumor-reactive γδ T cells for antibody-based cancer immunotherapy.
    Meraviglia S; Caccamo N; Guggino G; Tolomeo M; Siragusa S; Stassi G; Dieli F
    Curr Mol Med; 2010 Nov; 10(8):719-26. PubMed ID: 20937023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
    Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
    Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy.
    Rataj F; Jacobi SJ; Stoiber S; Asang F; Ogonek J; Tokarew N; Cadilha BL; van Puijenbroek E; Heise C; Duewell P; Endres S; Klein C; Kobold S
    Br J Cancer; 2019 Jan; 120(1):79-87. PubMed ID: 30429531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy.
    Alhallak K; Sun J; Wasden K; Guenthner N; O'Neal J; Muz B; King J; Kohnen D; Vij R; Achilefu S; DiPersio JF; Azab AK
    Leukemia; 2021 Aug; 35(8):2346-2357. PubMed ID: 33479469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agonist antibodies to TNFR molecules that costimulate T and NK cells.
    Melero I; Hirschhorn-Cymerman D; Morales-Kastresana A; Sanmamed MF; Wolchok JD
    Clin Cancer Res; 2013 Mar; 19(5):1044-53. PubMed ID: 23460535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving Immunotherapy Against B-Cell Malignancies Using γδ T-Cell-specific Stimulation and Therapeutic Monoclonal Antibodies.
    Hoeres T; Pretscher D; Holzmann E; Smetak M; Birkmann J; Triebel J; Bertsch T; Wilhelm M
    J Immunother; 2019; 42(9):331-344. PubMed ID: 31318724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function.
    Buchan SL; Dou L; Remer M; Booth SG; Dunn SN; Lai C; Semmrich M; Teige I; Mårtensson L; Penfold CA; Chan HTC; Willoughby JE; Mockridge CI; Dahal LN; Cleary KLS; James S; Rogel A; Kannisto P; Jernetz M; Williams EL; Healy E; Verbeek JS; Johnson PWM; Frendéus B; Cragg MS; Glennie MJ; Gray JC; Al-Shamkhani A; Beers SA
    Immunity; 2018 Nov; 49(5):958-970.e7. PubMed ID: 30446386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy.
    Houot R; Kohrt HE; Marabelle A; Levy R
    Trends Immunol; 2011 Nov; 32(11):510-6. PubMed ID: 21907000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.
    Smits NC; Coupet TA; Godbersen C; Sentman CL
    Expert Opin Biol Ther; 2016 Sep; 16(9):1105-12. PubMed ID: 27248342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
    Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
    J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments.
    Moreno-Vicente J; Willoughby JE; Taylor MC; Booth SG; English VL; Williams EL; Penfold CA; Mockridge CI; Inzhelevskaya T; Kim J; Chan HTC; Cragg MS; Gray JC; Beers SA
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Monospecificity of Novel Anti-HLA-E Monoclonal Antibodies Enables Reliable Immunodiagnosis, Immunomodulation of HLA-E, and Upregulation of CD8+ T Lymphocytes.
    Ravindranath MH; Terasaki PI; Pham T; Jucaud V
    Monoclon Antib Immunodiagn Immunother; 2015 Jun; 34(3):135-53. PubMed ID: 26090591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy.
    Tomala J; Chmelova H; Mrkvan T; Rihova B; Kovar M
    J Immunol; 2009 Oct; 183(8):4904-12. PubMed ID: 19801515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.